ECSP099404A - Anticuerpos humanos contra el ligando 4 de tipo delta humano - Google Patents

Anticuerpos humanos contra el ligando 4 de tipo delta humano

Info

Publication number
ECSP099404A
ECSP099404A EC2009009404A ECSP099404A ECSP099404A EC SP099404 A ECSP099404 A EC SP099404A EC 2009009404 A EC2009009404 A EC 2009009404A EC SP099404 A ECSP099404 A EC SP099404A EC SP099404 A ECSP099404 A EC SP099404A
Authority
EC
Ecuador
Prior art keywords
human
league
antibodies against
delta type
antibody
Prior art date
Application number
EC2009009404A
Other languages
English (en)
Inventor
Joel H Martin
Eric Smith
Nicholas J Papadopoulos
Irene Noguera-Troise
Gavin Thurston
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ECSP099404A publication Critical patent/ECSP099404A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un anticuerpo humano aislado o un fragmento de un anticuerpo humano que se fija específicamente al ligando 4 delta-like humano (hDll4) y bloquea la unión de hDll4 a un receptor Notch. El anticuerpo anti-DII4 humano o el fragmento de anticuerpo fija hDll4 con una afinidad de ? 500 pM, según se mide por resonancia de plasmón superficial.
EC2009009404A 2006-12-14 2009-06-11 Anticuerpos humanos contra el ligando 4 de tipo delta humano ECSP099404A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87492206P 2006-12-14 2006-12-14
US91641507P 2007-05-07 2007-05-07
US98532307P 2007-11-05 2007-11-05

Publications (1)

Publication Number Publication Date
ECSP099404A true ECSP099404A (es) 2009-07-31

Family

ID=39491524

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009404A ECSP099404A (es) 2006-12-14 2009-06-11 Anticuerpos humanos contra el ligando 4 de tipo delta humano

Country Status (32)

Country Link
US (9) US7919593B2 (es)
EP (2) EP2423227A1 (es)
JP (2) JP5677744B2 (es)
KR (1) KR101516569B1 (es)
CN (1) CN101611055B (es)
AU (1) AU2007334366B2 (es)
CA (1) CA2672622C (es)
CR (1) CR10863A (es)
CY (1) CY1113087T1 (es)
DK (1) DK2115003T3 (es)
DO (1) DOP2009000140A (es)
EC (1) ECSP099404A (es)
ES (1) ES2386480T3 (es)
GT (1) GT200900167A (es)
HR (1) HRP20120536T1 (es)
IL (1) IL198612A (es)
MA (1) MA31092B1 (es)
ME (1) ME00812B (es)
MX (2) MX2009005963A (es)
MY (1) MY164461A (es)
NI (1) NI200900115A (es)
NO (1) NO347649B1 (es)
NZ (1) NZ577616A (es)
PL (1) PL2115003T3 (es)
PT (1) PT2115003E (es)
RS (1) RS52439B (es)
RU (1) RU2448979C2 (es)
SG (2) SG177189A1 (es)
SI (1) SI2115003T1 (es)
SV (1) SV2009003296A (es)
TN (1) TN2009000245A1 (es)
WO (1) WO2008076379A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11208461B2 (en) 2014-07-18 2021-12-28 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US7906116B2 (en) * 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
CA2664738C (en) * 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
US20110091447A1 (en) * 2008-03-13 2011-04-21 The Hospital For Sick Children Lymphocyte control of obesity and insulin resistance
PT3456190T (pt) 2008-06-27 2022-02-15 Merus Nv Animal murino transgénico produtor de anticorpo
EP2307051B1 (en) 2008-07-08 2015-02-11 OncoMed Pharmaceuticals, Inc. Notch-binding agents and antagonists and methods of use thereof
US8124093B2 (en) 2008-07-16 2012-02-28 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
ES2662519T3 (es) * 2008-07-25 2018-04-06 Institute For Research In Biomedicine Anticuerpos neutralizantes contra el virus de la gripe A y usos de estos
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
AR073072A1 (es) * 2008-08-19 2010-10-13 Regeneron Pharma Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
EP2344536A1 (en) 2008-09-19 2011-07-20 MedImmune, LLC Antibodies directed to dll4 and uses thereof
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
TWI513465B (zh) * 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
CN102638971B (zh) * 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
MX336152B (es) * 2009-08-29 2016-01-08 Abbvie Inc Proteinas terapeutico de union a dll4.
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
UY32917A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
CA2782299A1 (en) * 2009-12-01 2011-06-09 Oncomed Pharmaceuticals, Inc. Methods for treating cancers comprising k-ras mutations
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011088215A2 (en) 2010-01-13 2011-07-21 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
JO3183B1 (ar) * 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US10143186B2 (en) 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
EP3072904A1 (en) 2010-03-02 2016-09-28 Abbvie Inc. Therapeutic dll4 binding proteins
US20110256135A1 (en) * 2010-03-17 2011-10-20 Wolfgang Fraunhofer Anti-nerve growth factor (ngf) antibody compositions
JP6050747B2 (ja) * 2010-06-17 2016-12-21 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー インフルエンザ受動免疫化に有用な抗体
EP3960865A1 (en) 2010-08-02 2022-03-02 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
WO2012054077A2 (en) * 2010-10-19 2012-04-26 Mayo Foundation For Medical Education And Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
WO2012092539A2 (en) * 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US20130078247A1 (en) 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
EP3954704A1 (en) 2011-06-03 2022-02-16 XOMA Technology Ltd. Antibodies specific for tgf-beta
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
CA2841551C (en) 2011-07-18 2020-07-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
HRP20192255T1 (hr) 2011-08-05 2020-03-06 Regeneron Pharmaceuticals, Inc. Humanizirani miševi s univerzalnim lakim lancem
AU2012299195B9 (en) 2011-08-19 2018-05-10 Regeneron Pharmaceuticals, Inc Anti-Tie2 antibodies uses thereof
BR112014006390A2 (pt) * 2011-09-19 2017-03-28 Kymab Ltd anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
JP6170496B2 (ja) 2011-09-23 2017-07-26 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
CA2849508C (en) 2011-09-30 2020-12-22 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
RS56330B1 (sr) 2011-10-28 2017-12-29 Regeneron Pharma Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
JP6325451B2 (ja) * 2011-12-02 2018-05-16 アイム・セラピューティクス・べー・フェー Ａ型インフルエンザに特異的な抗体
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
ME03477B (me) 2011-12-20 2020-01-20 Regeneron Pharma Miševi sa humanizovanim lakim lancem
DK2809681T3 (en) * 2012-01-31 2019-03-11 Regeneron Pharma ANTI-ASIC1 antibodies and uses thereof
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
PT2825037T (pt) 2012-03-16 2019-08-07 Regeneron Pharma Animais não humanos que expressam sequências de imunoglobulinas sensíveis ao ph
SMT201800395T1 (it) 2012-03-16 2018-09-13 Regeneron Pharma Anticorpi a catena leggera ingegnerizzati con istidina e roditori modificati geneticamente per la generazione degli stessi
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
RU2014141536A (ru) 2012-03-16 2016-05-10 Регенерон Фармасьютикалз, Инк. Мыши, которые продуцируют антигенсвязывающие белки с зависимыми от величины ph характеристиками связывания
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
JO3820B1 (ar) * 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
HK1206038A1 (en) * 2012-05-31 2015-12-31 Sorrento Therapeutics, Inc. Antigen binding protenins that bind dll-4
AR092325A1 (es) * 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
KR101535341B1 (ko) 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JP2015532272A (ja) 2012-09-28 2015-11-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二重アンジオポエチン−２／Ｄｌｌ４結合剤および抗ＶＥＧＦ−Ｒ剤を含む薬学的組み合わせ
JP6371294B2 (ja) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
BR112015010691A2 (pt) 2012-11-13 2017-08-22 Regeneron Pharma Anticorpo que se liga especificamente ao receptor de procineticina (prokr), seu uso no tratamento ou atenuação da dor e composição farmacêutica que o compreende
AR093445A1 (es) * 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
CN110192541B (zh) 2013-02-22 2022-02-18 瑞泽恩制药公司 表达人源化主要组织相容性复合物的小鼠
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
TR201910592T4 (tr) * 2013-07-09 2019-08-21 Ablbio Spesifik olarak dll4 ve vegf ye bağlanan yeni çift-hedefli protein ve bunun kullanımı.
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CA2922113C (en) 2013-08-23 2023-05-23 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
JP6535675B2 (ja) 2013-10-02 2019-06-26 メディミューン，エルエルシー 抗ａ型インフルエンザ抗体の中和及びその使用
CN105636986B (zh) 2013-10-18 2020-05-12 瑞泽恩制药公司 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
CN103804497A (zh) * 2014-03-06 2014-05-21 中国药科大学 一种抗人Delta like4单克隆抗体
RS59077B1 (sr) 2014-03-11 2019-09-30 Regeneron Pharma Anti-egfrviii antitela i njihova primena
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
BR112016021679A2 (pt) 2014-03-21 2018-12-04 Regeneron Pharmaceuticals, Inc. proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
SG10201808225TA (en) 2014-03-21 2018-10-30 Regeneron Pharma Non-human animals that make single domain binding proteins
CN113563462B (zh) 2014-07-15 2024-08-13 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
AU2015350075B2 (en) 2014-11-17 2021-06-03 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using CD3xCD20 bispecific antibody
AU2016212087B2 (en) 2015-01-28 2019-11-07 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
HK1250038A1 (zh) 2015-03-19 2018-11-23 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
KR20240142591A (ko) 2015-03-27 2024-09-30 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
KR20240132525A (ko) 2015-04-06 2024-09-03 리제너론 파아마슈티컬스, 인크. 비인간 동물에서의 인간화 t 세포 매개 면역반응
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
MX389708B (es) 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
CA2994412A1 (en) * 2015-07-31 2017-02-09 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting cd56 and uses thereof
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer
TWI784917B (zh) 2015-09-23 2022-11-21 美商再生元醫藥公司 最優化抗ｃｄ３雙特異性抗體及其用途
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
SG11201805001UA (en) 2016-01-13 2018-07-30 Medimmune Llc Method of treating influenza a
KR102885186B1 (ko) 2016-01-25 2025-11-17 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 그의 접합체, 및 사용 방법
US11026996B2 (en) * 2016-05-25 2021-06-08 The Trustees Of Columbia University In The City Of New York Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
KR102495601B1 (ko) 2016-06-10 2023-02-06 리제너론 파마슈티칼스 인코포레이티드 항-gitr 항체 및 그것의 사용
WO2018058001A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
HRP20221202T1 (hr) 2016-09-23 2022-12-09 Regeneron Pharmaceuticals, Inc. Anti-muc16 (mucin 16) antitijela
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US10925971B2 (en) 2016-11-29 2021-02-23 Regeneron Pharmaceuticals, Inc. Methods of treating PRLR positive breast cancer
EP3558347B1 (en) 2016-12-22 2026-01-21 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
SMT202100307T1 (it) * 2018-01-26 2021-07-12 Regeneron Pharma Anticorpi e frammenti di legame di anti-tmprss2
WO2019197676A1 (en) 2018-04-13 2019-10-17 Ludwig Institute For Cancer Research Ltd Heterodimeric inactivatable chimeric antigen receptors
IL278244B2 (en) 2018-04-30 2026-01-01 Regeneron Pharma Antibodies and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates and uses thereof
CN108752473B (zh) * 2018-05-03 2021-08-31 陕西师范大学 一种抗c5全人源单链抗体c5b3及其应用
CA3099547A1 (en) 2018-05-07 2019-11-14 Reshma Abdulla RANGWALA Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
IL280875B2 (en) 2018-08-31 2024-12-01 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
SG11202108525VA (en) 2019-02-21 2021-09-29 Regeneron Pharma Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
US20220119502A1 (en) * 2019-02-28 2022-04-21 Ann And Robert H. Lurie Children's Hospital Of Chicago Kawasaki disease antibodies identify hepacivirus peptides
WO2020257604A1 (en) 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation
JP7743313B2 (ja) 2019-06-21 2025-09-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
WO2021123908A1 (en) 2019-12-20 2021-06-24 Ludwig Institute For Cancer Research Ltd Car-t cell therapy targeting ngcgm3
CN111234003B (zh) * 2020-02-07 2022-02-01 中国人民解放军第四军医大学 一种用于癌症靶向治疗的短肽及基于其的超声响应纳米载药微泡和应用
MX2022010599A (es) 2020-02-28 2022-09-09 Regeneron Pharma Moleculas biespecificas de union al antigeno que se unen a her2, y metodos de uso de los mismos.
CN115244084A (zh) 2020-03-06 2022-10-25 瑞泽恩制药公司 抗gitr抗体及其用途
EP4121454A1 (en) * 2020-03-19 2023-01-25 Imperial College Innovations Limited Coronavirus antibody
DK4045533T5 (da) 2020-03-26 2024-07-29 Univ Vanderbilt Humane monoklonale antistoffer mod svær akut respiratorisk syndrom-coronavirus 2 (sars-cov-2)
WO2021195326A1 (en) * 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
EP4142739A2 (en) 2020-04-27 2023-03-08 Twist Bioscience Corporation Variant nucleic acid libraries for coronavirus
TWI809426B (zh) * 2020-06-19 2023-07-21 大陸商信達生物製藥（蘇州）有限公司 抗Ｃｌａｕｄｉｎ１８.２抗體以及其用途
KR20240038138A (ko) 2020-07-13 2024-03-22 리제너론 파마슈티칼스 인코포레이티드 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
NZ797493A (en) 2020-10-22 2024-05-31 Regeneron Pharma Anti-fgfr2 antibodies and methods of use thereof
WO2022103724A1 (en) 2020-11-10 2022-05-19 Regeneron Pharmaceuticals, Inc. Selenium antibody conjugates
JP2024505195A (ja) 2021-01-25 2024-02-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｐｄｇｆ－ｂ抗体及び肺動脈高血圧症（ｐａｈ）を治療するための使用方法
AU2022249328A1 (en) 2021-03-31 2023-09-21 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
CA3212850A1 (en) 2021-06-22 2022-12-29 Frank DELFINO Anti-egfrviii antibody drug conjugates and uses thereof
MX2024008640A (es) 2022-01-12 2024-07-24 Regeneron Pharma Analogos de camptotecina conjugados a un residuo de glutamina en una proteina y su uso.
WO2023196903A1 (en) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
CN119584978A (zh) 2022-06-07 2025-03-07 再生元制药公司 用于调节t细胞活性的多特异性分子及其用途
EP4626553A2 (en) 2022-11-30 2025-10-08 Regeneron Pharmaceuticals, Inc. Tlr7 agonists and antibody-drug-conjugates thereof
WO2024130165A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
WO2024138000A1 (en) 2022-12-21 2024-06-27 Regeneron Pharmaceuticals, Inc. Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
WO2025117727A1 (en) 2023-11-29 2025-06-05 Regeneron Pharmaceuticals, Inc. Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL101728A (en) * 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
ATE442373T1 (de) 1995-06-28 2009-09-15 Imp Cancer Res Tech Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden
EP0773288A3 (en) * 1995-08-29 1997-07-09 Kirin Brewery Chimera animal and its method of manufacture
US6337387B1 (en) 1995-11-17 2002-01-08 Asahi Kasei Kabushiki Kaisha Differentiation-suppressive polypeptide
US20030180784A1 (en) * 1997-04-04 2003-09-25 Millennium Pharmaceuticals, Inc. Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
US6121045A (en) * 1997-04-04 2000-09-19 Millennium Biotherapeutics, Inc. Human Delta3 nucleic acid molecules
AU6952498A (en) 1997-04-04 1998-10-30 Millenium Pharmaceuticals, Inc. Novel human delta3 compositions and therapeutic and diagnostic uses therefor
EP1004669B1 (en) * 1997-05-14 2007-04-18 Asahi Kasei Kabushiki Kaisha Novel differentiation inhibitor
WO2000006726A2 (en) 1998-07-27 2000-02-10 Amgen Inc. Delta-related polypeptides
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2003047470A (ja) 2001-08-01 2003-02-18 Asahi Kasei Corp 新規な抗体及びその用途
EP1517921B1 (en) * 2002-06-28 2006-06-07 Domantis Limited Dual specific ligands with increased serum half-life
WO2004024764A1 (en) * 2002-09-10 2004-03-25 Lorantis Limited Pharmaceutical composition and medical treatments comprising notch ligand proteins
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US20060134121A1 (en) * 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US20060175847A1 (en) * 2005-02-07 2006-08-10 Davis Blair C Magnetic doorknob with interchangeable design discs
AU2006287228B2 (en) * 2005-09-01 2012-12-13 Alora Biopharma, Inc. Methods for using and identifying modulators of Delta-like 4
JP5489465B2 (ja) * 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
KR20090016762A (ko) * 2006-06-06 2009-02-17 제넨테크, 인크. 혈관 발달을 조정하기 위한 조성물 및 방법
CA2654000A1 (en) * 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
CA2664738C (en) 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
TWI513465B (zh) * 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
JO3183B1 (ar) * 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
AR093445A1 (es) * 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11208461B2 (en) 2014-07-18 2021-12-28 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer

Also Published As

Publication number Publication date
IL198612A0 (en) 2011-08-01
JP5677744B2 (ja) 2015-02-25
ES2386480T3 (es) 2012-08-21
WO2008076379A8 (en) 2009-05-14
RU2448979C2 (ru) 2012-04-27
DK2115003T3 (da) 2012-07-09
US20110150905A1 (en) 2011-06-23
NO20092596L (no) 2009-07-08
EP2423227A1 (en) 2012-02-29
NI200900115A (es) 2010-03-10
EP2115003A2 (en) 2009-11-11
SG177189A1 (en) 2012-01-30
US20220025030A1 (en) 2022-01-27
US11820815B2 (en) 2023-11-21
WO2008076379A3 (en) 2008-09-18
CR10863A (es) 2009-07-23
US7919593B2 (en) 2011-04-05
MX358410B (es) 2018-08-20
KR101516569B1 (ko) 2015-05-07
KR20090088936A (ko) 2009-08-20
DOP2009000140A (es) 2009-07-15
EP2115003B1 (en) 2012-06-06
US7488806B2 (en) 2009-02-10
JP2014240412A (ja) 2014-12-25
MX2009005963A (es) 2009-06-17
CA2672622A1 (en) 2008-06-26
US20150191534A1 (en) 2015-07-09
US7534868B1 (en) 2009-05-19
HRP20120536T1 (hr) 2012-10-31
MY164461A (en) 2017-12-15
SG177193A1 (en) 2012-01-30
CN101611055A (zh) 2009-12-23
SV2009003296A (es) 2009-10-27
TN2009000245A1 (en) 2010-10-18
NZ577616A (en) 2011-06-30
US20080181899A1 (en) 2008-07-31
CY1113087T1 (el) 2016-04-13
US20170029492A1 (en) 2017-02-02
HK1138019A1 (en) 2010-08-13
MA31092B1 (fr) 2010-01-04
WO2008076379A2 (en) 2008-06-26
NO347649B1 (no) 2024-02-12
PL2115003T3 (pl) 2012-10-31
GT200900167A (es) 2011-08-08
AU2007334366B2 (en) 2014-02-06
AU2007334366A1 (en) 2008-06-26
SI2115003T1 (sl) 2012-08-31
ME00812B (me) 2013-02-28
CA2672622C (en) 2016-05-10
CN101611055B (zh) 2012-08-08
US20090142354A1 (en) 2009-06-04
IL198612A (en) 2013-07-31
US20150376267A1 (en) 2015-12-31
JP2010512749A (ja) 2010-04-30
RU2009126766A (ru) 2011-01-20
PT2115003E (pt) 2012-07-16
RS52439B (sr) 2013-02-28
BRPI0720021A2 (en) 2018-11-06
US20150232545A1 (en) 2015-08-20
US20090017035A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
ECSP099404A (es) Anticuerpos humanos contra el ligando 4 de tipo delta humano
NO2020036I1 (no) Isolert antistoff eller fragment derav omfattende lett kjede og tung kjede CDR-sekvenser ifølge NO344867 krav 1 (SEQ ID NO: 224, 225, 226 og 146, 147, 148), der antistoffet eller fragmentet derav binder human IL-17 reseptor A; spesielt et antistoff omfattende lett kjede og tung kjede variable domenesekvenser ifølge NO344867 krav 2 (SEQ ID NO: 40 and 14); slik som et IgG2 antistoff omfattende lett og tung kjede variable domenesekvenser ifølge NO344867 krav 4 (SEQ ID NO: 40 and 14); og spesielt brodalumab; og dets derivater dekket av NO344867.
NO20091758L (no) Hoyaffinitetshumane antistoffer til human IL-4 reseptor
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
CL2007001624A1 (es) Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular.
CY1122092T1 (el) Ιατρικη χρηση ανθρωπινων αντισωματων υψηλης συγγενειας κατα του ανθρωπινου υποδοχεα il-4
NO20084650L (no) Modifiserte humaniserte anti-interleukin-18 antistoffer
CY2018018I1 (el) Θεραπεια του οικογενους μεσογειακου πυρετου με αντι-il-1b αντισωματα
BRPI0510674A (pt) variantes fc otimizadas
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
CY1115437T1 (el) Υδροξυμεθυλοκυκλοεξυλαμινες
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
PL1987357T3 (pl) Polipeptydy rozpoznawane przez przeciwciała anty-Trichinella oraz ich zastosowanie
EP1976987A4 (en) NEW ANTIGEN IN CONNECTION WITH CANCER
SMAP201000056A (it) Elemento per il rivestimento di una superficie e relativo rivestimento, metodo per la realizzazione di un elemento per il rivestimento di una superficie e relativa macchina
GB0611708D0 (en) Novel antibodies against prion protein and uses thereof
NZ599097A (en) Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer
IT1392027B1 (it) Anticorpo monoclonale e suo uso per la identificazione della isoforma oncofetale della fibronettina (b-fn) a scopo diagnostico o terapeutico.
HN2009000575A (es) Anticuerpos humanos de alta afinidad para el receptor de il-4 humano
DOP2008000065A (es) Anticuerpos de alta afinidad hacia el receptor de il-6 humano.